SML3714
SMIP004-7
≥98% (HPLC)
Synonym(s):
2-Methyl-4-butylaniline, 4-Butyl-2-methylaniline, 4-Butyl-2-methylbenzenamine
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Empirical Formula (Hill Notation):
C11H17N
CAS Number:
Molecular Weight:
163.26
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.21
Recommended Products
Quality Level
Assay
≥98% (HPLC)
form
(Oil or liquid)
color
colorless to brown
storage temp.
-10 to -25°C
Biochem/physiol Actions
SMIP004-7 is a cell penetrant, potent and selective ubiquinone uncompetitive inhibitor of mitochondrial Complex I (NADH:ubiquinone oxidoreductase). SMIP004-7 selectively binds to a distinct N-terminal region of Complex I catalytic subunit NDUFS2, which leads to rapid disassembly of Complex I. SMIP004-7 potently inhibits growth of triple-negative breast cancer xenografts in mice.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Elizabeth Rico-Bautista et al.
Oncotarget, 4(8), 1212-1229 (2013-08-02)
We previously identified SMIP004 (N-(4-butyl-2-methyl-phenyl) acetamide) as a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells. SMIP004 decreased the levels of positive cell cycle regulators, upregulated cyclin-dependent kinase inhibitors, and resulted in G1 arrest, inhibition of colony
Metabolic targeting of cancer by a ubiquinone uncompetitive inhibitor of mitochondrial complex I
Cell Chemical Biology, 29(3), 436-450 (2022)
Gabriela Reyes-Castellanos et al.
Trends in pharmacological sciences, 43(9), 706-708 (2022-04-07)
Targeting metabolic reprogramming has proven successful in oncology, but this field requires better identification of drugs that inhibit mitochondrial metabolism in cancer cells. Recent work from Dr Wolf's group reveals that the primary target of the antitumor compound SMIP004-7 is
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service